Therapieempfehlungen für den Einsatz intravenös anwendbarer Immunglobuline

Medizinische Klinik

Volumn 91, Issue 3, 1996, Pages 141-147

  Marschner, Jens Peter ^a,b   Rietbröck, Norbert ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOGLOBIN; HEPATITIS B ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

HUMAN; INFECTION; INTRAVENOUS DRUG ADMINISTRATION; PASSIVE IMMUNIZATION; REVIEW; SEPSIS; AUTOIMMUNE DISEASE; CLINICAL PROTOCOL; IMMUNE DEFICIENCY; ORGAN TRANSPLANTATION;

AUTOIMMUNE DISEASES; CLINICAL PROTOCOLS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC DEFICIENCY SYNDROMES; INFECTION; ORGAN TRANSPLANTATION;

EID: 0030584487     PISSN: 07235003     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Arsura, E.: Experience with intraverious immunoglobulin in myasthenia gravis. Clin. Immunol. Immunopath. 53 (1989), 170-179
2. Babes, V., M. Lepp: Recherches sur la vaccination antirabique. Ann. Inst. Pasteur. 3 (1889), 385-390.
3. Berger, D.: Experimentelle Grundlagen der Endotoxin-Neutralisation durch polyklonale und polyvalente Immunglobuline. In: Lenz, K., A. N Laggner (Hrsg.): Intensivmedizinisches Seminar, Bd. 3, Springer, Berlin-Heidelberg-New York 1991, p. 229-240
4. Bismuth, A., J. L. Arulnaden, D. Samuel, M F. David, F. Pichon, D. Mathieu, H. Farahmand, P. Farrokhi, C. Feray, C. Brechot et al., Relaps prevention in liver transplant patients treated for liver involvement due to hepatitis B virus. Rev. franc. Transfus. Hemobiol. 35 (1992), 107-123.
5. Böger, R., S. Bode-Böger, J. C. Frolich: Intravenöse Immunglobuline. Grundlagen, Auswahlkriterien und Indikationen für ihren prophylaktischen und therapeutischen Einsatz. Med. Klin. (im Druck).
6. Bruton, O. C: Agammaglobulinemia. Pediatrics 9 (1952), 722-728
7. Bundesgesundheitsamt und Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe. Bekanntmachung über die Zulassung von Arzneimitteln. Bundesanzeiger Nr. 84 vom 4 5. 1994.
8. Bundesgesundheitsamt und Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe: Bekanntmachung über Maßnahmen zur Abwehr von Arzneimittelrisiken. Verminderung des Risikos der Ubertragung von hämatogenen Viren bei Arzneimitteln, die durch Fraktionierung aus Plasma humanen Ursprungs hergestellt werden Bundesanzeiger Nr. 161 vom 26, 8. 1994.
9. Calvelli, T A., A R. Rubinstein: Intravenous gammaglobulin in infant acquired imuno-deficiency syndrom. Pediat. infect. Dis. 5, Suppl, 3 (1986), 207-210.
10. Chapel, H. M., for the Consensus Panel for the Diagnosis and Management of Primary Antibody Deficiencies: Consensus on diagnosis and management of primary antibody deficiencies. Brit. med. J. 308 (1994), 581-585.
11. Chapel, H. M , M. Lee, R. Hargreaves, D. H, Pamphilon, A. G. Prenrice for the UK group of Immunoglobuline Replacement Therapy in Multiple Myeloma: Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myclome. Lancet 343 (1994), 1059-1063.
12. Cherin, P., S. Herson, B. Wechsler et al.: Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Amer. J Med. 91 (1991), 162-168.
13. Commission of the European Communities, Committee for Proprietary Medicinal Products: Medicinal products derived from human blood or plasma. Core summary of product Characteristics III/C/3 (1992), 51-111.
14. Conti, C. J., B. M. Freed, S. A. Gruber, N. Lempert: Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch. Surg. 129 (1994), 443-447.
15. Conti, D. J., B M. Freed, N. Lempert: Prophylactic immunoglobulin therapy improves die outcome of renal transplantation in recipients at risk for primary cytomegalovirus disease. Transplant. Proc 25 (1993), 1421-1422.
16. D'Alessandro, A. M., J. D. Pirsch, R. J. Stratta, H. W. Sollinger, M. Kayaloglu: Succesful treatment of severe cytomegalovirus infections with gangciclovir and CMV hyperimmune globulin in liver transplant patients. Transplant. Proc. 21 (1989), 3560-3561.
17. Davis, C. L.; The prevention of cytomegalovirus disease in renal transplantation. Amer. J. Kidney Dis. 16 (1990), 175-188.
18. Dominiom, L., R. Dionigi, M. Zanello, M. Chiaranda, R. Dionigi, A. Aquarolo, A. Ballabio, C. Sguotti: Effects of high-dose IgG on survivel of surgical patients with sepsis scores of 20 or greater. Arch. Surg, 126 (1991), 236-240.
19. Dwyer, J. M.: Manipulating the immune system with immune globuline. New Engl. J. Med. 326 (1992), 107-116
20. Engle, M. A., N. S. Fatica, J. B. Bussel, J. E. O'Loughlin, M. S. Snyder, M. L. Lesser: Clinical mal of single-dose intravenous gamma globulin in acute Kawasaki disease Amer. J. Dis Child 143 (1989), 1300-1304.
21. Ergaz, Z., I. Arad: Intravenous immunglobulin therapy in neonatal immune hemolytic jaundice. J. perinat Med. 21 (1993), 183-187.
22. Esnault, V. L. M., A Testa, D. R. W. Jayne, J.-P. Soulillou, J Guenel. Influence of immunoadsorption on the removal of immunoglobulin G autoantibodies in crescentic glomerulonephritis. Nephron 65 (1993), 180-184
23. European Pharmacopoea. Immunglobulinum humamim normale ad usum intravenosum. Pharm. Europ 2 (1994), 5-16.
24. Faed, J. M., B. Day, M. Pollock, P. K. Taylor, H. Nukada, J. D. Hammond-Tooke: High dose intravenous human immunoglobulin in chronic inflammatory demyelinating polyneuropathy. Neurology (Minneap.) 39 (1989), 422-425.
25. Fanaroff, A. A , S. B. Korones, L. L. Wright, E C. Wright, R. L. Poland, C. B Bauer, J. E. Tyson, J. B. Philips III, W. Edwards, J. F. Lucey, C. S. Catz, S. Shankaran: A controlled trial of intravenous immune globuline to reduce nosocomial infections in very-low-birth-weight infants. New Engl. J. Med. 330 (1994), 1107-1113
26. Fehr, J., V. Hoffmann, V. Kappeler: Transient reversal of thrombocytopenia in ideopathic thrombocytopenic purpura by high dose intravenous gamma globulin. New Engl. J. Med. 306 (1982), 1254-1258,
27. Fibiger, J : Om serum behandling af difteri. Hospitalstidende 6 (1889), 337-339
28. Flores G, C. Cunrungham-Rundles, A. C. Newland, J. B Bussel: Efficacy of intravenous immunoglobulin in the treatment of autoimmune anemia: results in 73 patients. Amer. J. Hemat. 44 (1993), 237-242.
29. Furusho, K., T. Kamiya, H Nakano et al.: High dose intravenous gammaglobulin for Kawasaki disease Lancet 2 (1984), 1055-1058.
30. Gajdos, P. H., H. Outin, D. Elkharrat: High dose intravenous gammaglobulin for myasthenia gravis. Lancer 1 (1984). 406-407.
31. Gelfand, E. W.: The use of intravenous immune globulin in collagen vascular disorders: a potentielly new modality of therapy. J. Allergy, clin Immunol. 84 (1989). 613-616.
32. Glowacki, L. S., F. M. Smaill: Meta-analysis of immune globulin prophylaxis in transplant recipients for the prevention of symptomatic cytomegalovirus disease. Transplant. Proc. 25 (1993), 1408-1410.
33. Gordon, B G., J. Kiwanuka, J. Kadushin. Autoimmune neutropenia and Hodgkin's disease: succesful treatment with intravenous gammaglobulin Amer. J. pediat Hemat. Oncol. 13 (1991), 164-167.
34. Gould, F. K., R. Freeman, C. E. Taylor, T. Ashcroft, J, H. Dark, P. A. Corris: Prophylaxis and management of cytomegalovirus pneumonits after lung transplantation: a review of experience in one center. J. Heart Lung Transplant, 12 (1993), 695-699.
35. Guglielmo, B.J., A Wong-Beringer, C. Linker Immune globulin therapy in allogenic bone marrow transplant: a critical review. Bone Marrow Transplant. 13 (1994), 499-510.
36. Hanada, T., K. Saito, T. Nagasawa: Intravenous gammaglobulin therapy for thromboneutropenic neonats of mothers with systemic lupus eryrhematosus. Europ. J. Haemat. 38(1987), 400-404.
37. Haque, K. N., M. H. Zaidi IgM-enriched intravenous immunoglobulin in neonatal sepsis. Amer. J. Dis Child. 142 (1988), 1293-1296.
38. Harder, S., R. Böger, S. Bode-Böger, B. Drewelow, J. Krappweis, J.-P. Marschner, K. H. Molz, A. Plangger, T. Szucs, J. Tepper, M. Theison, P. Thürmann (study group "Pharmacoeconomics and Rational Pharmacotherapy", GKPharm): Drug utilisation review in german hospitals ELCPA 47 (1994), A 102.
39. Hlava, J , I. Honl: Serum Vaccinum und seine Wirkungen. Wien. klin. Rundsch. 9 (1985), 6725-6727.
40. Ho, D. P., T. R. Rota, M. S. Hirsch: Antibody to lymphadenopathy-associated with virus in AIDS New Engl. J. Med. 312 (1985), 549-650.
41. Hutter, J. A., J. Scott, T. Wreghitt, T. Higenbottam, J. Wallwork: The importance of cytomegalovirus in heart-lung transplant recipients. Chest 95 (1989), 627-631.
42. Imbach, P.: Immunotherapy with intravenous immunoglobulins. Academic Press, London 1991.
43. Jablonski, H., O. Sander, R Willers, O. Adams, P. Bartmann, V. Wahn: The use of intravenous immunoglobulins in symptomatic HIV infection. Clin. Invest. 72 (1994), 220-224.
44. Jann, S., S. Beretta, M. Moggio, L. Adobbati, G. Pellegrini: High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J. Neurol. Neurosurg, Psychiat. 55 (1992), 60-62.
45. Jordan, S. C.: Intravenous gammaglobulin therapy in systemic lupus erythematosus and immune complex disease. Clin. Immunol, Immunopath 53 (1989), 164-169.
46. Keller, T., K. McGrath, A Newland, P. Gatenby, R. Cobcroft, J. Gibson: Indications for use of intravenous immunoglobulin. Recommendation of the Australasian Society of Blood Transfusion consensus symposium. Med J. Aust. 159 (1993), 204-206.
47. Klein, M , P, Kaminsky, M. Duc: Intravenous immune globulines in auto-immune diseases. Therapie 48 (1993), 97-103